title: Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices.
abstract: Tumor necrosis factor alpha (TNFα) is a multifunctional cytokine which plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA). Apart from its well recognized proinflammatory properties, it is known to interfere with lipid metabolism and erythropoiesis. We evaluated the effects of adalimumab on hematologic, lipid and inflammatory parameters using data from patients on adalimumab 40 mg fortnightly from 2 centers in Malaysia. Mean changes in laboratory values from baseline to Weeks 4, 12 and 24 were compared using paired T test and Wilcoxon signed-rank test. We studied 18 patients with RA who were on adalimumab 40 mg fortnightly. The inflammatory markers i.e. erythrocyte sedimentation rate and C reactive protein showed significant changes as early as at week 4 compared to baseline with p values of 0.003 and 0.005, respectively. From a baseline of high disease activity with a mean Disease Activity Score using 28 joint counts (DAS 28) of 5.3, there was a steady improvement in the disease activity and remission was achieved at week 24 with a DAS 28 of 2.4. The hemoglobin level improved at week 12 (p=0.013) and this was sustained till week 24. As opposed to previous studies, the LDL level significantly decreased at week 12 (p=0.015) and this change persisted till week 24 (p=0.001). The total cholesterol showed a similar pattern as the LDL. The pharmacodynamics of adalimumab therapy in rheumatoid arthritis extend beyond the joints with favorable effects on haemoglobin and lipid profile.
authors.affiliation: Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, 56000, Cheras, Kuala Lumpur, Malaysia.
authors.forename: R
authors.initials: R
authors.lastname: Sakthiswary
authors.affiliation: Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, 56000, Cheras, Kuala Lumpur, Malaysia.
authors.forename: S
authors.initials: S
authors.lastname: Syahrul Sazliyana
authors.affiliation: Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, 56000, Cheras, Kuala Lumpur, Malaysia.
authors.forename: M S
authors.initials: MS
authors.lastname: Mohd Shahrir
authors.affiliation: Department of Medicine, Putrajaya Hospital, 62250, Putrajaya, Malaysia.
authors.forename: N S
authors.initials: NS
authors.lastname: Shahril
authors.affiliation: Department of Medicine, Putrajaya Hospital, 62250, Putrajaya, Malaysia.
authors.forename: H
authors.initials: H
authors.lastname: Hussein
keywords: adalimumab; anemia; lipid profile; rheumatoid arthritis